Report of Foreign Issuer (6-k)
January 07 2019 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
January 7, 2019
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CR Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
On January 7, 2019, ProQR Therapeutics N.V. issued a press release titled, ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Lebers Congenital Amaurosis 10. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference into the Companys registration statement on Form F-3 (File No. 333-228251).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
|
|
Date: January 7, 2019
|
By:
|
/s/ Smital Shah
|
|
|
Smital Shah
|
|
|
Chief Financial Officer
|
4
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024